Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Revenue of Vigil Neuroscience, Inc. (VIGL)
Revenue in 2023 (TTM): $
According to Vigil Neuroscience, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Vigil Neuroscience, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-399,000 | $-88,467,000 | $-82,638,000 | $-82,638,000 |
| 2022 | $ | $-1,010,000 | $-67,295,000 | $-68,305,000 | $-67,726,000 |
| 2021 | $ | $-345,000 | $-42,938,000 | $-43,283,000 | $-43,252,000 |
| 2020 | $ | $ | $-28,546,000 | $-28,546,000 | $-28,546,000 |